One of the more noticeable aspects of stubborn fat is a double chin. A common cosmetic concern across the country, a double chin can make a person appear heavier or older than they actually may be, resulting in a compromise in their self-confidence. One of the most sought-after non-surgical treatments to address a double chin today is Kybella. We offer a Kybella course here at the Aesthetic Institute of Massachusetts to not only benefit your patients but your practice’s success.
Approved by the FDA, Kybella is a renowned minimally invasive treatment to eliminate stubborn fat beneath the chin. Deoxycholic acid is the key to addressing a double chin. Naturally produced in the body, this molecule helps break down fat cells. This safe and effective body sculpting formula is administered through a very fine needle into the targeted area where it instantly begins working to break down stubborn fat. One of the unique qualities about Kybella is that it progressively helps eliminate a double chin; once chin fat has been destroyed, the formula continues to prevent a future double chin from taking the former’s place.
Our Kybella course offers a comprehensive educational experience that includes:
- An overview of Kybella
- Injection guidance and technique
- Aftercare instructions
- And more
Kybella has become a leading treatment in the aesthetic industry that has helped not only patients achieve their aesthetic goals but has greatly contributed to the success of practice’s across the country.
Following our Kybella course, you will be able to:
- Discuss with your patients about Kybella and how they can benefit
- Proficiently administer Kybella to your patients through highly effective techniques
- Better devise optimal treatment plans for your patients and help satisfy their cosmetic goals
- And more
Kybella can not only help people of all genders and skin tones achieve redefined facial contours but it can also contribute to your practice’s success. If you are interested in learning more about our Kybella course, contact us today.